Medtronic launches diabetes system with Abbott’s Instinct sensor

GALWAY, Ireland - Medtronic (NYSE:MDT) announced Tuesday the broad U.S. commercial launch of its MiniMed 780G system integrated with the Instinct sensor, manufactured by Abbott specifically for Medtronic’s systems. The healthcare equipment giant, with a market capitalization of $132 billion, has seen its stock surge 25.37% over the past six months, trading near its 52-week high of $106.33.

The launch follows FDA clearance earlier this year for the integration of the two technologies. The system is now shipping to customers across the United States. According to InvestingPro data, Medtronic has demonstrated solid revenue growth of 5.34% over the last twelve months, with analysts forecasting 8% growth for fiscal year 2026.

The Instinct sensor, based on Abbott’s CGM technology, provides real-time glucose readings that the MiniMed 780G system uses to automatically adjust insulin delivery every five minutes. According to the company, the sensor can be worn for up to 15 days.

"This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes, in the press release.

The Instinct sensor joins Medtronic’s sensor portfolio, which includes the recently launched Simplera Sync sensor and the Guardian 4 sensor.

Dr. Steve Edelman, founder and director of Taking Control of Your Diabetes, noted in the announcement that feedback from the early customer pilot program has been positive, matching what he and colleagues have observed in clinical settings.

The MiniMed 780G system automatically adjusts insulin based on glucose readings to help reduce highs and lows in blood sugar levels. The company states the Instinct sensor is designed to be smaller and thinner than previous models, providing up to 15 days of wear with fewer insertions required.

Medtronic, headquartered in Galway, Ireland, develops and manufactures various healthcare technologies including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. The company maintains a strong financial position with a "Good" overall financial health score of 3.0 according to InvestingPro, and has maintained dividend payments for 49 consecutive years with a current yield of 2.75%. While trading at a relatively high P/E ratio of 28.17 compared to its earnings growth, Medtronic remains a prominent player in the Healthcare Equipment & Supplies industry.Want deeper insights into Medtronic’s valuation and growth prospects? InvestingPro offers comprehensive Pro Research Reports on MDT and 1,400+ other US equities, transforming complex Wall Street data into actionable intelligence for smarter investing decisions.

In other recent news, Medtronic has reported strong fiscal second-quarter results, exceeding expectations in both sales and earnings. The company’s performance was driven by growth in its Cardiovascular and Neuroscience segments, which helped offset slower growth in its Medical Surgical and Diabetes divisions. Following these results, several analyst firms have adjusted their price targets for Medtronic. Truist Securities raised its price target to $110, citing strength in the company’s Pulsed Field Ablation technology and expected momentum in renal denervation. UBS increased its price target to $102, highlighting organic sales growth. RBC Capital set a new price target of $118, emphasizing growth acceleration. Bernstein SocGen Group raised its target to $111, noting Medtronic’s commitment to growth investments and earnings leverage. Mizuho set the highest target at $125, pointing to strong momentum in the company’s renal denervation therapy. These developments reflect a positive outlook from analysts on Medtronic’s growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.